| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Departments of Medical Biochemistry and Clinical Neurosciences [A. P., Q. S., M. E. W.], Medical Biochemistry [R. N. J., D. E.], Oncology and Clinical Neurosciences [V. W. Y.], and Clinical Neurosciences and Pediatrics [P. F.], The University of Calgary, Calgary, Alberta, T2N 4N2 Canada; Departments of Medicine [D. M., P. F.] and Epidemiology, Prevention, and Screening [P. M. A. B.], Tom Baker Cancer Centre [A. P., Q. S., M. E. W.], Calgary, Alberta, T2N 4N2 Canada; Pathology Department, Foothills Hospital, Calgary, Alberta, Canada [N. B. R.]; Departments of Pharmacology and Ophthalmology Research, Agouron Pharmaceuticals, Inc., San Diego, California [D. S., H. Z., K. A.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The MMPs are the principal secreted proteinases required for extracellular matrix degradation in a variety of physiological and pathological tissue remodelling processes, including wound healing, embryo implantation, tumor invasion, metastasis, and angiogenesis (8, 9, 10) . At least 18 MMPs have been described (7 , 11) , which are subdivided into the collagenases, stromelysins, gelatinases, and membrane-type MMPs (12) . Their activities are tightly controlled at the levels of gene transcription, zymogen activation by proteolysis, and inhibition of active forms by the TIMPs (13) . There is a wealth of evidence for an association between either deregulated production or activation of MMPs and aggressive or invasive behavior in a variety of human cancers (14, 15, 16, 17, 18) . Similarly, evidence that MMPs are involved in invasion and angiogenesis in gliomas comes from observations that gelatinase-A (MMP-2), gelatinase-B (MMP-9), and MT1-MMP have been found in several glioma cell lines and surgical specimens (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35) , that gelatinase-A or gelatinase-B protein is localized to the tumor microvasculature (28 , 29 , 34) , and that the amount of MMP overexpression correlates with glioma grade (28 , 29 , 35) .
A number of low molecular weight synthetic MMP inhibitors are under development by the pharmaceutical industry. In general, these have a peptide backbone similar to the cleavage site on collagen that binds the MMP, and they contain a hydroxamate group that coordinates the catalytic zinc ion in the active site (36) . Several promising studies have been published that find antitumor activity of synthetic MMP inhibitors in a variety of in vivo tumor models. The most widely studied of these is batimastat (also called BB-94; British Biotech Ltd., Oxford, United Kingdom), which produced prolonged survival in an ovarian tumor xenograft (37) ; inhibited metastasis of melanoma (38) , breast (39) , and colon cancer (40) cell lines; and inhibited growth of a colon cancer xenograft (41) , a breast cancer cell line (42) , and a hemangioma (43) . Other synthetic MMP inhibitors (Celltech Therapeutics, Ltd., Slough, United Kingdom) inhibit the growth of prostate, melanoma (44) , and lung cancer cell lines (45) . There are no published studies regarding the use of synthetic MMP inhibitors in malignant gliomas.
AG3340 is a novel synthetic MMP inhibitor (Agouron Pharmaceuticals) that selectively inhibits critical MMPs at picomolar concentrations. AG3340 has one of the lowest Kis for gelatinase-A and gelatinase-B (50–150 pM). It has a low molecular weight (Mr 423.5), is lipophilic, and crosses the blood-brain barrier.5 These properties are critical if AG3340 is to be used clinically in the treatment of gliomas; preliminary results in a number of tumor models show AG3340 has antitumor activity (46, 47, 48, 49, 50) . In the present study, we were interested in determining whether AG3340 would inhibit glioma invasion or growth of the human malignant glioma cell line U87. We observed a marked reduction in tumor invasion and a profound inhibition of tumor growth and cellular proliferation with AG3340 treatment.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
80% confluence, harvested by trypsin treatment, and replaced in DMEM-F12/10% FCS.
Tumor Implantation.
Female SCID-NOD mice (Cross Cancer Institute, Edmonton, Alberta), 6–8 weeks of age, were used. For injection into animals, cells were grown to 80% confluence, harvested, counted using a hemocytometer, rinsed twice in PBS (Life Technologies, Inc.), and resuspended at a density of 2.0 x 106 cells/50 µl in PBS. For s.c. injection, the cell suspension was drawn up to 0.2 ml in a syringe for each injection, with a 26-gauge, 3/8-inch intradermal needle, and 2.0 x 106 injected s.c. into a volume of 50 µl above the midfemur region of the left hind limb of the mouse. So that we studied only established and growing tumors, the lesions were allowed to grow until their average size was approximately 0.5 x 0.5 cm (after about 3 weeks). The mice were then randomized to treatment with either vehicle control or AG3340 on day 0. Tumor cross-sectional area was measured twice weekly and calculated by multiplying the length x width. On the day of sacrifice, tumor height was also measured, and tumor volumes were estimated by multiplying length x width x height x 0.5 (42)
. Tumor areas for each treatment group were averaged and compared using the Wilcoxon test. The Wilcoxon test was used because of the heterogeneity of variance of tumor area between these two groups. We performed two series of experiments (series 1 and 2) to characterize tumor growth and histologically analyze the tumors produced (Fig. 1)
. Animals were sacrificed as a group when they became moribund (i.e., had trouble with ambulation or feeding). In series 1, the purpose of the experiments was to compare tumor size between the AG3340 and control groups. To control for the duration of treatment and tumor size when examining the histological characteristics of these tumors, half of the AG3340 group was sacrificed on the same day as the control group (i.e., to control for duration), and the other half of the AG3340 group was allowed to grow until sacrifice was indicated (i.e., when the tumors were the same size as those in the much earlier sacrificed control group). In series 2, the purpose of the experiments was to identify the earlier mechanisms of glioma growth inhibition by examining tumor samples from mice with tumors that were smaller and treated for shorter periods of time than in series 1.
|
Sample Preparation.
Tumors were dissected and excised in situ, briefly washed with saline to remove excess blood, and divided into three parts. We preserved the tumor-host architecture during dissection by collecting both the overlying skin and underlying muscle (and bone where appropriate). One part was placed in 10% formalin, embedded in paraffin, sectioned, and stained with H&E and with antibodies to GFAP (Dako, Copenhagen, Denmark) for routine histological examination. A second part, consisting only of tumor (i.e., without skin, bone, etc.) was snap frozen in liquid nitrogen and stored at -70°C for zymographic analysis. The final third was placed in Tissue-Tek O.C.T. Compound (Sakura Finetek, Torrance, CA) and then snap frozen and stored at -70°C. The liver and lungs were also excised, placed in formalin, and processed as described above. Three mice (two in AG3340 and one in the control group) had to be sacrificed on weekends, and their tissue was unavailable for analysis.
Analysis of Proliferation Using BrdUrd.
We used the technique of immunostaining for BrdUrd as a measure of cellular proliferation in experiment 2 (51)
. Briefly, mice received injections of BrdUrd (100 mg/kg) i.p. 1 h before sacrifice; then tumor tissues were collected, fixed in 10% formalin, and sectioned in paraffin. Sections were then deparaffinized and hydrated. Sections were treated with 2 N HCl for 10 min to denature DNA, followed by 0.1 M sodium borate to neutralize the HCl. BSA (0.3%) was then added to block nonspecific binding, and sections were incubated with a mouse monoclonal anti-BrdUrd antibody (1:10, Becton Dickinson) overnight at 4°C. Goat anti-mouse IgG conjugated with biotin (1:100) was added for 60 min, and sections were then incubated with Streptavidin-FITC (1:100), counterstained with propidium iodide (10µg/ml), and mounted with Gelvatol. Sections were visualized using an immunofluorescence microscope equipped with appropriate filters. The number of BrdUrd-positive nuclei was counted in the most cellular areas of the tumor and defined as a proportion of total nuclei stained with propidium iodide in the same fields (x1000; oil immersion) and compared using the 
2 test.
Analysis of Apoptosis.
Apoptotic cells were labeled using the ApoTag in situ detection kit (Oncor, Oncogene Research Products). Briefly, paraffin slides were deparaffinized followed by digoxigenin-dUTP labeling of apoptotic fragmented DNA 3'OH ends. The subsequent steps involved binding of fluorescein-conjugated anti-digoxigenin antibody and viewing by epifluorescence. Counterstaining was done using propidium iodide. The average number of positive nuclei was recorded and defined as a proportion of total nuclei stained with propidium iodide in three high power (x400) fields.
Analysis of Vascularization.
We assessed vascularization in tumors that were processed to paraffin blocks, cut into 8-µm-thick sections, and stained with rabbit antisera to laminin (Sigma). Briefly, laminin antisera stains vascular basal lamina and is a reliable marker of vessel growth in brain tumors. We followed the methods described elsewhere (52)
, except enzyme digestion was done with trypsin for 2 h. Sections were counterstained with hematoxylin (to optimize assessment of general tissue morphology), dehydrated, and mounted in Permont (Fisher). Development time was the same for controls and experimental slides and performed in parallel. All controls performed were negative. The paraffin section of each tumor with the greatest cross-sectional area was selected, stained as above, assigned a code number by one investigator (Q. S.), and read by an observer (P. F.) blinded to the particular experiment or treatment group. The total number of vessel profiles per high powered field (x250) was counted, and the tumor regions were categorized (e.g., margin, proliferating tumor, necrotic area, and others) in adjacent microscopic fields across the maximum tumor diameter ranging from the tumors inferior border, through the center of the tumor to the region adjacent to the skin. Four to 17 fields/tumor were counted (depending on tumor diameter), spanning the total diameter of solid tumor and excluding the fields where the tumor cells infiltrated into the underlying muscle. For each tumor specimen, the number of laminin-positive profiles/field was averaged and compared using the Wilcoxon rank sums test.
Zymographic Analysis.
This in vitro assay uses gelatin-substrate gel electrophoresis to measure the levels of metalloproteinase activity in tumor samples. Frozen tumor tissues from series 1 (n = 32) were pulverized in liquid nitrogen and homogenized in buffer [0.5 M Tris-HCl (pH 7.6), 0.2 M NaCl, 10 mM CaCl2, and 1% Triton X-100] in an Ultra-Turrax-25 homogenizer. Ten µg of total protein from homogenate supernatants were electrophoresed on 10% SDS polyacrylamide gels containing 1 mg/ml of gelatin. Gels were washed overnight in washing buffer [50 mM Tris-HCI (pH 8.0), 5 mM CaCl2, and 2.5% Triton X-100] and then incubated for 24 h at 37°C in the above buffer without Triton-X 100 so that renaturation of enzyme could occur. Gels were stained with Coomassie blue and destained. Gelatinolytic activities were visualized as clear bands against a blue background (35)
. Recombinant human TIMP-1 was a gift of Dr. Andrew Docherty (Celltech, Slough, United Kingdom).
Histological Examination.
Histological sections were reviewed in a double-blind fashion by an anatomical neuropathologist (N. B. R,), described and compared for series 1 and 2. The following were evaluated: (a) muscle invasion (scored on a 0–4 scale, where 0 was absent and 4 is marked); (b) number of mitoses per high powered field (the average of three randomly selected fields at x400); (c) presence of metastases in the lungs or liver (0, none; 1, present); (d) amount of vascularity (0–3 scale, where 0 is absent and 3 is prominent); and (e) amount of necrosis (estimation of amount of necrosis as percentage of total tumor). The number of mitoses, tumor volume, proportion of apoptotic nuclei, and proportion of BrdUrd-staining nuclei were compared using Wilcoxon’s two-sample test, and discrete measures (invasion, necrosis, cellularity, and atypia) were compared using Fisher’s Exact test.
Assessment of in Vitro Cell Growth with Treatment of AG3340.
Tumor cell viability and proliferation were studied in vitro using both BrdUrd and [3H]thymidine labeling. U87 cells were seeded at a density of 104 cells on glass coverslips (Thermanox; Nalge Nunc International). Cells were treated with either AG3340 (10 µM) or vehicle control. BrdUrd labeling (Amersham) was carried out for 60 min at 37°C in DMEM supplemented with 10% FCS. Subsequently, the cells were washed in PBS and fixed in ethanol for 30 min at -20°C. Anti-BrdUrd mouse monoclonal antibodies (Becton Dickinson) were applied for 1 h, and coverslips were washed in PBS. The mouse monoclonal antibody was detected by immunofluorescence with FITC-conjugated rabbit anti-mouse. [3H]Thymidine uptake was also determined as a measure of cellular proliferation. Cells were seeded and allowed 2 h to adhere, 1 ml of feeding medium (containing 10% fetal bovine serum) was added to each well, and various concentrations of AG3340 were added. All experiments were done in replicates of three. After a 48-h incubation, cells were pulsed with 1 Ci of [3H]thymidine/ml for a period of 16 h before being harvested. To measure thymidine incorporation, coverslips were washed four times in PBS, placed in scintillation vials containing 5 ml of scintillation fluid (Ecolume; ICN), and placed in a Betascan beta counter (LS 5000CE; Beckman).
Plasma Concentrations of AG3340.
We determined plasma concentrations of AG3340 in the 16 animals in experiment 2B on the day the animals were sacrificed; the levels at 1 h (n = 4) and 24 h (n = 4) after the last dose of AG3340 were analyzed. Animals were anesthetized with 1 ml of metofane by inhalation (Janssen Pharmaceutical, Canada), and 0.8 ml of blood was collected by cardiac puncture, placed in glass tubes with sodium heparin (Becton Dickinson, NJ), then centrifuged at 104 rpm for 10 min. The serum was stored at -70°C.
AG3340 and an internal standard (AG3347) were extracted from mouse plasma and analyzed for AG3340 content by UV HPLC analysis. Briefly, 100 µl of plasma were mixed with 1 ml of acetonitrile, vortexed for 1 min, and cetrifuged for 15 min at 4000 rpm. The supernatant was removed and dried at 50°C under nitrogen. AG3340 was solubilized in 120 µl of mobile phase prior to injection onto the HPLC column. Chromatographic detection was performed on a reverse phase column (Columbus, 5µm, C18, 150 x 3.2 mm) with a flow rate of 0.5 ml/min. The mobile phase was 20% acetonitrile/50 mM NH4HPO4/0.01 M triethylamine (pH 3.2). Detection of AG3340 was at 240 nm. The percentage of extraction efficiency of AG3340 was determined using the internal standard, and AG3340 concentrations were calculated from a standard curve prepared at the time of assay. The quality controls for AG3340 did not vary more than 15% of the theoretical value. AG3340 concentrations were back-calculated to ng/ml in plasma.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. A significant difference in tumor size between the two groups appeared by day 21 [0.42 cm (2)
versus 0.75 cm2, P < 0.004, Wilcoxon test] and remained until day 31 [0.65 cm (2)
versus 2.93 cm2, P < 0.0009, Wilcoxon test] when the control group (n = 8) needed to be sacrificed because the mice were moribund. On the same day, several animals from the AG3340 group were sacrificed (n = 3) electively; one animal in the AG3340 group died during an i.p. injection (from an i.p. hemorrhage; autopsy proven) on day 38, and data for this animal were combined with the other AG3340 animals sacrificed on day 31. The others (n = 4) in the AG3340 group were allowed to grow until sacrifice was needed on day 70. The length of survival for the AG3340 group was 2.3 times greater than the control group. The tumor size between the control group on day 31 and the AG3340 mice sacrificed on day 70 was not significantly different [2.93 cm (2)
versus 2.38 cm2; P < 0.55, Wilcoxon test]. This experiment was repeated (n = 16) with nearly identical results (Fig. 1B)
. In series 2, the animals were sacrificed earlier and with smaller tumors, and again significant inhibition of tumor growth was seen (Fig. 1, C and D)
.
Effects of AG3340 on Tumor Invasion and Proliferation.
We examined the histological sections on all tumors and found significantly more invasion into the underlying muscle in the control group than the AG3340 group (Table 1)
. In series 1, the proportion of tumors with no or minor (a score of 0 or 1) muscle invasion was 6 of 14 (43%) in the AG3340 group but only 1 of 15 (6.7%) in the control group (P < 0.035, Fisher’s Exact test). This was true for AG3340 animals that were sacrificed on day 31 with the control animals and for tumors taken on day 70 when they had reached the same size as tumors in the control group. Furthermore, the type of muscle invasion was striking in the control group, where the tumor invasion frequently eroded into the muscle and completely engulfed the muscle fibers, giving the appearance of isolated "islands" of muscle in a sheet of tumor cells (Fig. 2)
. In most cases in the AG3340 group, we saw a layer of inflammatory cells (GFAP negative) between the tumor and the muscle layer. This suggested the possibility that AG3340 interfered with invasion, although inflammation was present.
|
|
. In experiment 2A, where the tumors were smaller and sampled after a shorter duration of treatment, the proliferative indices (mitotic count and BrdUrd staining) were reduced in the treatment group, but the amount of invasion was the same in the treatment and control groups. In experiment 2B, where the tumors were larger than in experiment 2A, there was some invasion in the AG3340 group (33% had some invasion), and all of the control tumors had invaded the underlying muscles. These data suggested that the changes in proliferation were more marked and occurred earlier than differences in tumor invasion between the two groups.
Other Histological Features.
The amount of necrosis was not significantly different between the control and AG3340-treated groups. Similarly, there were no hepatic or pulmonary metastases in either group.
Effects of AG3340 on Apoptosis.
The terminal deoxynucleotidyltransferase-mediated nick end labeling assay was used to determine whether there was a difference between treatment and control groups in the rate of apoptosis. There was no significant difference in the amount of apoptosis seen between the treatment and control groups in animals sacrificed at the same time (Table 1)
. In series 1, tumors from mice sacrificed on day 70 had a larger proportion of apoptotic nuclei than those from animals sacrificed on day 31 (7.7 versus 1.86%, P = 0.0467, Wilcox test).
Effects of AG3340 on Tumor Vascularity.
There was no significant difference in the amount of vascularity seen between the treatment and control groups in experiments 1A, 1B, or 2A; we did not perform vascular staining on tumor samples from experiment 2B (Table 1)
.
Gelatinase Activity in Tumor Samples.
Considerable variation in gelatinase activity, as visualized by zymography, was seen but did not differ between treatment groups (Fig. 3)
. Samples from both groups show the presence of inactive gelatinases and a small amount of active forms. That no differences were observed between the AG3340 and control groups is probably due to the dissociation of the inhibitor-MMP complex during sample preparation.
|
. Samples from conditioned medium from a BHK (baby hamster kidney) cell line stably transfected with a human gelatinase-B expression vector were run on a zymographic gel, and gelatinolytic activity was inhibited in vitro by incubating the gels overnight with various concentrations of AG3340. Gelatinolytic activity of all samples was inhibited by 1 nM AG3340; almost total inhibition was seen at concentrations above 1 µM. Inhibition of gelatinases at 10 nM was superior to that achieved with 100 ng/ml of recombinant TIMP-1.
|
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Overall, these changes produced a significant prolongation of survival in AG3340-treated animals compared with controls. The mechanism of growth inhibition in vivo is unknown. Although there were more apoptotic cells in AG3340-treated tumors compared with tumors from control animals, which were allowed to grow to maximum size, there was no significant difference in apoptosis at earlier times of treatment with AG3340. Neither did we observe a striking increase in apoptosis or a change in tumor vascularity to account for the difference in tumor size. Furthermore, there was no significant inhibition of tumor growth in vitro, even at high micromolar levels of AG3340, suggesting that growth inhibition was seen only in the in vivo environment. We could not exclude the possibility that there were small differences in tumor vascularity or vascular perfusion that were undetectable by us but had significant effects on tumor growth.
The striking growth inhibition produced by AG3340 is surprising because we expected to observe primarily an inhibition of invasion; MMP inhibitors have been thought to primarily affect invasion and metastases. The mechanism by which AG3340 or any other synthetic metalloproteinase inhibitor inhibits tumor growth in vivo is unknown, although growth inhibition has been found in a variety of in vivo models (37, 38, 39 , 41 , 44) . Like AG3340, BB-94 does not have cytotoxic or cytostatic activity on cell lines in vitro, whose growth as tumors it inhibits in vivo (38 , 41) . MMP inhibitors have classically been thought to affect tumors by blocking invasion and metastasis and by inhibiting angiogenesis (53) . AG3340 has antiangiogenic effects in vivo,5 but we were unable to detect them using these methods; this would not appear to be its main site of action in the U87 model. Furthermore, when others examined melanoma cell lines treated with BB94 using endothelial cell markers or vascular basement membrane staining (38) , no differences in vascularity were seen. However, AG3340 decreased angiogenesis in lung, colon, and prostate cancer tumors in vivo.5 As expected, AG3340 also reduced tumor invasion. These data suggested that AG3340 (and perhaps other MMP inhibitors) inhibited tumor growth primarily through a mechanism that may inhibit in vivo cellular proliferation. We are testing the possibility that AG3340 may act indirectly to regulate cell growth, such as by inhibiting the release of mitogenic factors anchored in the extracellular matrix around the implanted tumors. This would account for the lack of growth inhibition in vitro and the striking inhibition of growth seen in vivo and has been reported as a mechanism with AG3340 in human colon tumors in vivo (47) .
These findings highlight the expanding appreciation for the multifunctional roles of MMPs, TIMPs, and synthetic MMP inhibitors in cancer biology. The accepted role of MMPs in cancer growth and metastasis is to facilitate extracellular matrix breakdown to allow intravasation and extravasation, but it is becoming clear that their actions are more complex; these molecules may affect cellular proliferation and other steps in the metastatic process (54 , 55) . Recent evidence from intravital video microscopic examination of cells undergoing extravasation has shown that this process occurs independently of the expression of MMPs and their inhibitors (56) . This has led to the suggestion that MMPs may be important in creating and maintaining a favorable growth environment for primary tumors and metastases (54) . Several recent reports suggest potential mechanisms through which MMPs may indirectly stimulate growth in vivo by influencing growth factor bioavailability. One such mechanism involves liberation of IGFs from their soluble binding proteins (IGFBPs). MMP-1, MMP-2, and MMP-3 can degrade IGFBP-3, thus releasing active IGF (57) . Also, MMP-3 can cleave the membrane-anchored precursor form of heparin-binding epidermal growth factor-like growth factor, releasing active heparin-binding epidermal growth factor that can act on cells in a paracrine or autocrine fashion (58) . MMPs may also negate mechanisms designed to moderate cytokine signals, as occurs in cleavage and release of the inactive type II cell surface "decoy" receptor for interleukin 1 (59) . Any or all of these types of events may be occurring in the tumor microenvironment but particularly at the tumor-stromal interface. It is attractive to speculate that such mechanisms may explain the paradox of the ability of AG3340 to inhibit tumor growth in vivo without any significant action on proliferation in vitro, because the abundant supply of growth-promoting substances in serum-containing cell culture medium may override subtle cellular control of growth factor bioavailability.
Another potentially confounding factor is that TIMPs might not always act as strict antagonists of tumor metastasis, because a number of studies have reported stimulatory effects of TIMPs on cell growth that may be independent of their MMP-inhibiting capabilities. Several investigators found that TIMP levels were not negatively correlated with the degree of tumor malignancy, as would be expected if decreased TIMP production led to a more malignant phenotype. Somewhat paradoxically, TIMP expression increased with the degree of malignancy in several cancer types (58, 59, 60, 61, 62, 63) , including gliomas (64) . Others have reported that experimental manipulation of TIMPs can inhibit tumor growth; for example, TIMP-2 overexpression reduced melanoma growth but not metastases (65) , and transfection of TIMP-2 into transformed fibroblasts reduced metastases as well as tumor growth (66) . Finally, TIMP-1 and TIMP-2 are being recognized as potentially important cell signaling molecules. TIMP-1 stimulates proliferation in erythroid precursors (67 , 68) and a number of cell types in vitro in the absence of serum (69 , 70) and is a potent activator of steroidogenesis in germ cells (71) . Furthermore, the eythroid-potentiating activity of TIMP-1 is independent of its MMP-inhibitory activity (72) . Similarly TIMP-2 also has growth-promoting activity for a broad range of cells in vitro in the picomolar range (72) but inhibits basic fibroblast growth factor-induced endothelial proliferation (74) . Whether TIMPs will be growth stimulators or inhibitors may be tissue specific, or as appears to be the case with TIMP-2, they may be comitogens that depend for their actions on other factors such as insulin (70) . It is also possible that synthetic MMP inhibitors may affect tumor growth independent of their MMP-inhibitory activity.
In summary, this study is the first step in demonstrating the potential efficacy of AG3340 in human glioma growth and invasion. We are presently testing this MMP inhibitor in an orthotopic intracerebral human glioma model to determine whether it is effective in that model and reaches sufficient intratumoral concentrations. Finally, we are combining AG3340 with radiotherapy and chemotherapy. It is likely that AG3340 will be the most useful as cancer therapy when combined with conventional treatments.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by the Alberta Cancer Board, a generous donation from TransCanada Pipelines (Partners in Health), and Agouron Pharmaceuticals. 
2 These two authors share senior authorship.
3 To whom requests for reprints should be addressed, at Tom Baker Cancer Center, 1331 29th Street N.W., Calgary, Alberta, T2N 4N2 Canada. Phone: (403) 670-2000; Fax: (403) 283-1651.
4 The abbreviations used are: MMP, matrix metalloproteinase; GFAP, glial fibrillary acidic protein; BrdUrd, bromodeoxyuridine; TIMP, tissue inhibitor of metalloproteinase; IGF, insulin-like growth factor.
5 B. Shetty, personal communication.
Received 7/ 6/98; revised 1/ 5/99; accepted 1/ 6/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Sarkar, R. K. Nuttall, S. Liu, D. R. Edwards, and V. W. Yong Tenascin-C Stimulates Glioma Cell Invasion through Matrix Metalloproteinase-12 Cancer Res., December 15, 2006; 66(24): 11771 - 11780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Smookler, F. F. Mohammed, Z. Kassiri, G. S. Duncan, T. W. Mak, and R. Khokha Cutting Edge: Tissue Inhibitor of Metalloproteinase 3 Regulates TNF-Dependent Systemic Inflammation J. Immunol., January 15, 2006; 176(2): 721 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, S. Sarkar, and V.W. Yong The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase Carcinogenesis, December 1, 2005; 26(12): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L.M. Lamfers, D. Gianni, C.-H. Tung, S. Idema, F. H.E. Schagen, J. E. Carette, P. H.A. Quax, V. W. Van Beusechem, W. P. Vandertop, C. M.F. Dirven, et al. Tissue Inhibitor of Metalloproteinase-3 Expression from an Oncolytic Adenovirus Inhibits Matrix Metalloproteinase Activity In vivo without Affecting Antitumor Efficacy in Malignant Glioma Cancer Res., October 15, 2005; 65(20): 9398 - 9405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bissett, K. J. O'Byrne, J. von Pawel, U. Gatzemeier, A. Price, M. Nicolson, R. Mercier, E. Mazabel, C. Penning, M. H. Zhang, et al. Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2005; 23(4): 842 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Chantrain, H. Shimada, S. Jodele, S. Groshen, W. Ye, D. R. Shalinsky, Z. Werb, L. M. Coussens, and Y. A. DeClerck Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment Cancer Res., March 1, 2004; 64(5): 1675 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chhokar and A. L. Tucker Angiogenesis: Basic Mechanisms and Clinical Applications Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 253 - 280. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Hu, P. Guo, Q. Fang, H.-Q. Tao, D. Wang, M. Nagane, H.-J. Su Huang, Y. Gunji, R. Nishikawa, K. Alitalo, et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2 PNAS, July 22, 2003; 100(15): 8904 - 8909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Le, A. Besson, D. K. Fogg, K.-S. Choi, D. M. Waisman, C. G. Goodyer, B. Rewcastle, and V. W. Yong Exploitation of Astrocytes by Glioma Cells to Facilitate Invasiveness: A Mechanism Involving Matrix Metalloproteinase-2 and the Urokinase-Type Plasminogen Activator-Plasmin Cascade J. Neurosci., May 15, 2003; 23(10): 4034 - 4043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Bernardo, S. Brown, Z.-H. Li, R. Fridman, and S. Mobashery Design, Synthesis, and Characterization of Potent, Slow-binding Inhibitors That Are Selective for Gelatinases J. Biol. Chem., March 22, 2002; 277(13): 11201 - 11207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hoekstra, F.A.L.M. Eskens, and J. Verweij Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives Oncologist, October 1, 2001; 6(5): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hidalgo and S. G. Eckhardt Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kondraganti, S. Mohanam, S. K. Chintala, Y. Kin, S. L. Jasti, C. Nirmala, S. S. Lakka, Y. Adachi, A. P. Kyritsis, F. Ali-Osman, et al. Selective Suppression of Matrix Metalloproteinase-9 in Human Glioblastoma Cells by Antisense Gene Transfer Impairs Glioblastoma Cell Invasion Cancer Res., December 1, 2000; 60(24): 6851 - 6855. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian Matrix Metalloproteinases: Biologic Activity and Clinical Implications J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Shalinsky, J. Brekken, H. Zou, L. A. Bloom, C. D. McDermott, S. Zook, N. M. Varki, and K. Appelt Marked Antiangiogenic and Antitumor Efficacy of AG3340 in Chemoresistant Human Non-Small Cell Lung Cancer Tumors: Single Agent and Combination Chemotherapy Studies Clin. Cancer Res., July 1, 1999; 5(7): 1905 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bremer, S. Bredow, U. Mahmood, R. Weissleder, and C.-H. Tung Optical Imaging of Matrix Metalloproteinase-2 Activity in Tumors: Feasibility Study in a Mouse Model Radiology, November 1, 2001; 221(2): 523 - 529. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
, AG3340-treated group; 
, vehicle control-treated group. Bars, SD.
), 48 (
), and 72 (
) h. At 1 mM AG3340, cytotoxicity is apparent. All values represent the mean of quadruplicate wells; bars, SE. B, [3H]thymidine uptake was determined in U87 glioma cells after incubation with AG3340 for 48 h. Thymidine uptake was significantly inhibited only at doses of 1 mM AG3340. All values represent the mean of quadruplicate wells; bars, SE. C, BrdUrd staining showed similar results to those found in A and B; AG3340 showed no significant effect on the rate of cell proliferation.